BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

The World’s Most Recognizable Beverage Brand Is Up 33% in a Year. The Filed Numbers Tell a More Complicated Story.

Moe Alsumidaie by Moe Alsumidaie
September 18, 2026
in Bargains & Bubbles
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

First, the shape of it

Coca-Cola’s filed results for the most recent quarter show a business genuinely accelerating: revenue up 7%, earnings per share up 16%, and management raising its full-year guidance. The stock, meanwhile, trades at a price-to-sales ratio our data places in the 99th percentile of its own decade, meaning the market is paying more for each dollar of Coke’s sales than at almost any point in the last ten years. A business improving and a stock priced as if improvement is already banked: that gap is the story.

What the bulls are saying, loudly

On September 15, 2026, UBS named Coca-Cola its top consumer pick, expecting mid-single-digit organic revenue growth and low-double-digit earnings growth. The next day, Piper Sandler reiterated an “Overweight” rating and a $95 implied valuation level, citing what it called “best-in-class execution.” TD Cowen raised its target to $100. Of the analysts tracked as of mid-September, the overwhelming majority carry a positive or strong-positive rating. The consensus is about as one-sided as it gets.

The case they’re making isn’t invented. Coca-Cola’s Q2 2026 earnings release, published July 28, showed organic revenue growth of 6% for the quarter, global unit case volume up 5%, and Coca-Cola Zero Sugar alone growing at a double-digit pace. Those are not the numbers of a company coasting on its logo. Management responded by raising full-year 2026 guidance to roughly mid-single-digit organic revenue growth and high-single-digit to low-double-digit comparable earnings-per-share growth. The business, on the surface, is delivering.

So the bull case rests on real evidence. The question worth asking is what the price already assumes.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Coca-Cola and 500+ other names, on the same official data.See the evidence engine →

What the filings actually show

Start with the decade-long arc. Coca-Cola spent most of the 2010s shedding its bottling operations, handing the capital-heavy work of filling and shipping cans to independent partners. That shift, combined with acquisitions of Costa Coffee, Fairlife, and BodyArmor, remade the company into something closer to a brand licensor than a beverage manufacturer. The strategy paid off slowly, then quickly: the 10-K filed February 20, 2026 shows a gross margin of 61.6% for fiscal year 2025, up from the prior year, meaning Coke keeps more than sixty cents of every revenue dollar before paying for marketing, administration, or anything else. That is a genuinely unusual figure for a company selling a physical product.

Free cash flow for fiscal year 2025 reached $5.3 billion, up nearly 12% from 2024. These are the numbers that fund the dividend, and they are growing.

The most recent quarter extends the trend. The 10-Q for the quarter ended July 3, 2026 shows net revenues of $13.38 billion, with net income up 16% from the same quarter a year earlier. Earnings per share of $1.03 for a single quarter is a strong result by any measure.

The dividend picture is similarly solid. The annualized dividend sits comfortably below the full-year earnings per share the company posted for 2025, and management projects roughly $12.2 billion in free cash flow for 2026, a figure that covers the dividend many times over. For income-oriented analysis, the filed numbers show the dividend well-covered by both earnings and projected free cash flow, a picture the filings themselves support.

Where the math and the mood diverge

Here is where the conversation gets harder. “The math” is what the filed fundamentals justify on their own terms. “The mood” is what the market is currently paying on top of that. Right now, the mood is generous to a degree the decade’s history rarely supports.

BullScope TerminalYou just read Coca-Cola’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

At $88.06 per share, Coca-Cola trades at a price-to-earnings ratio modestly above its own ten-year median, according to our data. That premium is modest. The price-to-sales ratio tells a sharper story: 8.0 times revenue, against a decade median of 6.6, placing the current valuation in the 99th percentile of its own history. Think of it this way: a business that earns tens of billions annually in revenue is being valued at more than eight times what it takes in each year. At the decade median, the same revenue base would imply a meaningfully lower price.

Investing.com noted on September 16 that Coca-Cola appears “priced for optimism, not an obvious bargain,” with its valuation model estimating roughly 11% downside from what it calculates as fair value. Zacks Research flagged that Coke’s forward price-to-earnings multiple sits well above its industry average, a gap of more than six turns. Morgan Stanley’s published target of $87 sits below the current price entirely.

The debt load deserves a look too. Total debt as of the July 2026 filing stands at $43.5 billion, a figure larger than the company’s entire annual revenue. The interest coverage ratio of roughly 12.7 times means operating income covers interest payments comfortably, and net leverage sits below management’s own target range. The debt is manageable at current earnings levels. It becomes a different conversation if earnings soften.

The claim the filed numbers cannot yet answer

The loudest bull argument is that Coca-Cola’s volume acceleration signals a structural shift rather than a post-pandemic bounce. If that’s right, the premium valuation has a foundation. If volume growth reverts toward the low single digits that characterized most of the 2018-to-2023 period, the math supporting the current earnings multiple gets thinner. The filed numbers through July 2026 are consistent with the optimistic reading. They do not yet confirm it.

We cannot tell from the filings alone whether the volume trend holds into the back half of 2026. Management’s raised guidance implies confidence. The history of consumer staples companies, which tend to grow roughly in line with nominal economic growth over long periods, counsels patience before treating one strong quarter as a new baseline.

Reading the numbers

  • Q2 2026 net revenue: $13.38 billion, up 7% year over year. Source: Q2 2026 earnings release. What it means: the business is growing faster than its recent trend. A company that grew revenue just under 2% for all of 2025 posted 7% in a single quarter. Example: if a corner store that usually adds $7 in new sales per week suddenly adds $35, the owner notices, but also wonders whether it lasts.
  • Price-to-sales ratio: 8.0 times, 99th percentile of the decade. Source: our data, computed from SEC filings and market prices. What it means: the market is paying more for each dollar of Coke’s revenue than at almost any point in the last ten years. Example: a landlord who usually rents a flat for six times annual rent is now asking eight times. The flat is the same flat.
  • FY2025 free cash flow: $5.3 billion, up nearly 12%. Source: 10-K filed February 20, 2026. What it means: cash the business generates after maintaining its operations is growing, which is what funds the dividend and any future investment. Example: a household earning $100,000 that saves $11,000 after all bills is in a stronger position than one saving $9,800 the year before.
  • Total debt: $43.5 billion as of July 3, 2026. Source: 10-Q for quarter ended July 3, 2026. What it means: the company owes more than a full year of revenue to creditors. Interest coverage of roughly 12.7 times means earnings cover those payments easily today. Example: a household earning $80,000 a year carrying a mortgage where the annual payment is about $6,300 is stretched on paper but comfortable in practice, as long as the income holds.
  • Annualized dividend: $2.12 per share, against $3.04 in FY2025 earnings per share. Source: Q2 2026 press release and FY2025 10-K. What it means: the company pays out roughly seventy cents of every dollar it earns, keeping the rest. The income stream looks well-supported by current earnings and cash flow.

If the volume acceleration management reported in Q2 2026 proves durable and earnings land at the higher end of the raised guidance range, the current multiple sits closer to its historical norm than the price-to-sales figure alone suggests. If growth reverts, the premium built into the price-to-sales ratio has less to stand on. Those two outcomes, not any single filed number, are the central tension the filed evidence presents.

Sources

  • 10-Q for quarter ended July 3, 2026 (SEC EDGAR)
  • 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
  • Coca-Cola Q2 2026 press release (investor relations)
  • Coca-Cola Q2 2026 full earnings release (PDF)
  • Zacks Investment Research, September 16, 2026
  • Investing.com analysis, September 16, 2026
  • 247 Wall St., September 15, 2026
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Coca-Cola’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway

by Moe Alsumidaie
October 22, 2026
0

Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady healthcare conglomerate into a growth story. Then the...

Read moreDetails

The $14 Acquisition Price and the Arbitrage Gap the Market Is Pricing

by Moe Alsumidaie
October 16, 2026
0

The short version Sun Pharmaceutical agreed in April 2026 to buy Organon for $14.00 a share in cash, a deal Organon shareholders approved in July. The stock trades...

Read moreDetails

From $8 to $0.45: Ascend Wellness Is Generating Real Cash While the Market Prices It for Failure

by Moe Alsumidaie
October 14, 2026
0

The story, briefly The math, meaning what the filed numbers actually show, tells a story of a cannabis retailer that turned cash-flow positive in 2023 and has been...

Read moreDetails

ADMA Biologics: A Business Earning Real Money, Priced Like It Might Not

by Moe Alsumidaie
October 13, 2026
0

Six years ago, ADMA Biologics was losing nearly two dollars for every dollar it brought in. The company made a single class of medicine, plasma-derived immunoglobulins (proteins collected...

Read moreDetails

Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.

by Moe Alsumidaie
October 9, 2026
0

The share price is up 72% over the past twelve months. Revenue has fallen every single year since 2021. Those two facts belong to the same company, and...

Read moreDetails
Next Post

USANA: The Cash Is Real, the Loss Is Not, and the Customer Count Is the Story

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

ANI Pharmaceuticals: The Stock Fell While the Business Grew. The Gap Invites Scrutiny.

September 23, 2026

Home Depot: The Stock Is Down a Fifth, the Business Just Beat Estimates. Something Has to Give.

August 27, 2026

Evidence Sheet: General Electric (GE)

October 22, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.